|
Synonyms: TAK-079 | TAK079
Compound class:
Antibody
Comment: Mezagitamab (TAK-079) is a humanized, IgG1, cell-depleting anti-CD38 monoclonal antibody [3-4]. Anti-CD38 therapeutics were primarily developed as treatments for multiple myeloma [5], but have subsequently been discovered to offer potential in solid tumours and autoimmune diseases [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| TAK‐079 has been advanced to Phase 2 evaluation in clinical trial NCT04159805, which will determine efficacy of anti-CD38 treatment in the antibody-mediated autoimmune disease myasthenia gravis. Additional trials are underway for multiple myeloma (MM) and systemic lupus erythematosus (SLE). Click here to link to ClinicalTrials.gov's full list of TAK‐079 studies. The FDA granted TAK‐079 orphan designation for the treatment of MM in January 2019. |
